NHS urges investigation of 4 million women for polyendocrine metabolic ovarian syndrome

On Friday, the NHS issued new guidance recommending that up to 4 million women with irregular periods be screened for polyendocrine metabolic ovarian syndrome (PMOS). This condition, previously known as polycystic ovarian syndrome, is underdiagnosed and inconsistently treated, according to Nice.

Understanding Polyendocrine Metabolic Ovarian Syndrome

PMOS is estimated to impact up to 13% of women of reproductive age, based on data from the World Health Organization. The condition can lead to a range of health issues, including infertility and metabolic disorders.

Despite its prevalence, many women remain unaware of their condition due to lack of proper diagnosis and treatment. The NHS guidance aims to improve awareness and encourage healthcare providers to take a proactive approach in identifying and managing PMOS.

Importance of Early Diagnosis and Management

Early diagnosis of PMOS is crucial for effective management and prevention of complications. Symptoms can vary widely, making it essential for women experiencing irregular periods to seek medical advice.

Healthcare professionals are encouraged to consider PMOS in their assessments, particularly for those with a family history of the syndrome or related metabolic issues. Awareness and education are key to ensuring better health outcomes for affected women.